NCT04251026 - A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

February 28, 2031

Study Completion Date

February 28, 2031

Conditions

Mucopolysaccharidosis II

Interventions

DRUG

tividenofusp alfa

Intravenous repeating dose

Trial Locations (7)

UNC Children's Research Institute, Chapel Hill

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

UCSF Benioff Children's Hospital, Oakland

"UPMC , Children's Hospital of Pittsburgh"

McGill University Health Centre - Royal Victoria Hospital, Montreal

Erasmus Medical Center, Rotterdam

St Mary's Hospital, Manchester Academic Health Science Centre, Manchester